AI Maverick Intel Inc. (OTC: AIMV) has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc., granting the company exclusive review and matching capabilities for third-party offers on specific HEAL assets or business units. The agreement, effective February 11, 2026, provides AIMV with potential acquisition access across HEAL's portfolio of artificial intelligence-driven healthcare technology and services operating in more than six countries.
Under the terms of the arrangement, AI Maverick Intel will issue 120,000,000 common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million. The right of first refusal agreement will remain in place for three years unless terminated earlier by mutual agreement between the two companies. This strategic arrangement positions AI Maverick Intel to potentially acquire valuable healthcare technology assets that align with its focus on opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries.
The agreement's significance extends beyond the immediate financial terms, as it provides AI Maverick Intel with a strategic advantage in the rapidly evolving healthcare technology sector. By securing first refusal rights, the company gains privileged access to HEAL's portfolio without immediate acquisition obligations, allowing for careful evaluation of market conditions and asset performance. This approach reflects the company's stated strategy of evaluating strategic acquisitions, partnerships, and technology platforms designed to create scalable growth opportunities and long-term shareholder value.
For the healthcare technology industry, this development highlights the increasing convergence between artificial intelligence platforms and healthcare services across international markets. HEAL Group's operations in more than six countries suggest the potential assets under consideration have multinational applications and scalability. The right of first refusal mechanism represents a sophisticated approach to corporate development in the technology sector, allowing companies to secure future opportunities while managing current resource allocation.
The broader implications for investors and industry observers include potential consolidation in the healthcare AI space and the strategic positioning of smaller technology companies to access valuable assets through innovative agreement structures. The three-year timeframe provides both companies with flexibility to respond to market developments while maintaining strategic alignment. Additional information about AI Maverick Intel is available through the company's newsroom at http://ibn.fm/AIMV.
This agreement represents a strategic positioning move in the competitive healthcare technology landscape, where artificial intelligence applications are increasingly transforming service delivery, diagnostics, and patient care management across international markets. The right of first refusal structure allows AI Maverick Intel to monitor the performance and market reception of HEAL's assets while maintaining acquisition optionality, potentially creating a more informed basis for future strategic decisions in the healthcare technology sector.
